Dechloro Rivaroxaban is a highly potent and selective Factor Xa inhibitor with an oral bioavailability, exhibiting a Ki of 0.4 nM against free FXa, effectively inhibiting prothrombin and fibrinogen-related FXa activity with IC50 values of 2.1 nM and 92 nM, respectively.

Asundexian is an orally active FXIa inhibitor that effectively and reversibly binds to the active site of FXIa, with an IC50 of 1 nM. This compound is suitable for research on thrombotic diseases, particularly in the development of anticoagulants.

CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa.

Rivaroxaban impurity is an impurity of rivaroxaban, used to ensure drug purity and study its effects.

Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban is an oral, selective, and effective factor Xa (FXa) inhibitor used for stroke prevention.

Betrixaban is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM (inhibition of Factor 10a).

Edoxaban is an orally active factor Xa inhibitor with a Ki of 0.561 nM for human free FXa. It is used for the prevention and treatment of venous thromboembolism and has demonstrated superior anticoagulant properties in clinical trials.

5-R-Rivaroxaban is the (R) enantiomer of Rivaroxaban, an oral Xa factor inhibitor, being developed for the prevention and treatment of thromboembolic diseases.

Fondaparinux sodium is a pentasaccharide inhibitor of antithrombin-dependent factor Xa (IC50 = 40 nM). It can bind to antithrombin III.

Darexaban is a potent and orally effective factor Xa inhibitor with IC50 value of 54.6nM.

Apixaban is a direct factor Xa inhibitor with an IC50 of 0.08 nM and 0.17 nM in human and rabbit, respectively.

Edoxaban tosylate is the tosylate salt form of Edoxaban with identical activity, exhibiting a Ki of 0.561 nM for FXa. It is utilized in clinical studies for stroke prevention and thromboembolic disease.

Rivaroxaban is an inhibitor of factor Xa (FXa) with IC50 of 0.7 nM and Ki of 0.4 nM which developed for the treatment of thrombotic disease.

Enoxaparin is one of the most commonly used low-molecular-weight heparins in a wide variety of thromboembolic disorders and has several advantages over unfractionated heparin.